Skip to main content
. 2016 Mar 20;7(16):22928–22938. doi: 10.18632/oncotarget.8216

Table 3. Adverse events by frequency and grade in entire study population (N = 48).

Adverse Event Grade Total (N) %
1 2 3 4 5
Fatigue 12 13 2 27 56.3
Anemia 9 6 3 18 37.5
Anorexia 16 2 18 37.5
Dyspnea 9 5 1 1 1 17 35.4
Cough 14 2 16 33.3
Nausea 14 14 29.2
Hyponatremia 12 12 25
Hyperglycemia 8 2 1 11 22.9
Headache 8 2 10 20.8
Lymphopenia 6 1 3 10 20.8
Pain abdomen 8 1 1 10 20.8
Pain back 8 2 10 20.8
Sensory neuropathy 8 2 10 20.8
Diarrhea 8 1 9 18.8
Constipation 4 3 7 14.6
Elevated alkaline phosphatase 4 1 2 7 14.6
Rash 5 2 7 14.6
Dehydration 3 2 1 6 12.5
Elevated creatinine 6 6 12.5
Thrombocytopenia 6 6 12.5
Vomiting 6 6 12.5
Edema peripheral 3 1 1 5 10.4
Neutropenia 5 5 10.4
Pain shoulder 3 2 5 10.4
Fever 3 1 4 8.3
Hyperkalemia 4 4 8.3
Light sensitivity 4 4 8.3
Pain leg 2 2 4 8.3
Proteinuria 3 1 4 8.3
Dyspnea on exertion 3 1 4 8.3
Dizziness 1 1 1 3 6.3
Elevated bun 3 3 6.3
Hypocalcemia 1 2 3 6.3
Hypokalemia 2 1 3 6.3
Elevated prothrombin time 2 1 3 6.3
Insomnia 3 3 6.3
Leukocytosis 3 3 6.3
Pain hip 1 2 3 6.3
Pain knee 3 3 6.3
Tingling extremities 3 3 6.3
Urine color change 1 2 3 6.3
Vision blurred 3 3 6.3
Weakness 2 1 3 6.3
Weight loss 3 3 6.3
Urinary tract infection 2 1 3 6.3
Hypophysitis 3 3 6.3